Asian safinamide deal with Meiji Seika a partial salve for Newron
This article was originally published in Scrip
Executive Summary
An Asian licensing deal with Meiji Seika Pharma for the Parkinson's disease drug safinamide should give Newron Pharmaceuticals at least some breathing space after the double whammy it suffered last year.